Day One Biopharmaceuticals, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.

The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) news page on Stock Titan aggregates company announcements, clinical updates, financial results, and corporate developments for this commercial-stage oncology biopharmaceutical company. Day One describes itself as dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, with a strong emphasis on pediatric cancer and rare cancers.

Investors and followers of DAWN can use this news feed to review updates on OJEMDA™ (tovorafenib), Day One’s Type II RAF kinase inhibitor indicated for certain BRAF-altered pediatric low-grade gliomas. Company press releases cover pivotal and follow-up data from the FIREFLY-1 Phase 2 trial, the ongoing FIREFLY-2/LOGGIC Phase 3 trial in front-line pLGG, and regulatory designations such as Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug status described in Day One’s communications.

The feed also captures financial results and guidance, including OJEMDA net product revenue trends, license revenue from ex-U.S. commercial rights, and reported cash, cash equivalents, and short-term investments. These updates are often accompanied by conference call details and investor presentations referenced in the company’s Form 8-K filings.

Another important category of DAWN news involves pipeline and portfolio developments. This includes progress in the Phase 1a/1b trial of DAY301, a PTK7-targeted antibody-drug conjugate, and the addition of Emi-Le (emiltatug ledadotin), a B7-H4–targeted ADC for adenoid cystic carcinoma, through the acquisition of Mersana Therapeutics. Corporate announcements around this acquisition, as well as participation in industry and investor conferences such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, are also reflected.

By reviewing this curated stream of official press releases and related disclosures, users can follow how Day One reports clinical milestones, commercial performance for OJEMDA, and strategic decisions that shape its oncology pipeline. Bookmarking the DAWN news page provides a centralized view of these developments as they are released.